Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial
参考文献:1. Potenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273鈥?81 304-3959(90)90004-W" target="_blank" title="It opens in new window">CrossRef 2. Simmonds MA (1999) Management of breakthrough pain due to cancer. Oncology (Williston Park) 13:1103鈥?108 3. Bennett D, Burton AW, Fishman S et al (2005) Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2. Management. Pharmacol Ther 30:354鈥?61 4. Actiq SPC (2012) Cephalon Ltd, UK 5. Bredenberg S, Duberg M, Lennernas B et al (2003) In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 20:327鈥?34 3.07.002" target="_blank" title="It opens in new window">CrossRef 6. Streisand JB, Busch MA, Egan TD et al (1998) Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88:305鈥?09 802000-00006" target="_blank" title="It opens in new window">CrossRef 7. Lennernas B, Hedner T, Holmberg M et al (2004) Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 59:249鈥?53 365-2125.2004.02264.x" target="_blank" title="It opens in new window">CrossRef 8. England R, Maddocks M, Manderson C et al (2011) How practical are transmucosal fentanyl products for breakthrough cancer pain? novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care 1:349鈥?51 36/bmjspcare-2011-000037" target="_blank" title="It opens in new window">CrossRef 9. Christie JM, Simmonds M, Patt R et al (1998) Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16:3238鈥?245 10. Payne R, Coluzzi P, Hart L et al (2011) Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manag 22:575鈥?83 885-3924(01)00306-2" target="_blank" title="It opens in new window">CrossRef 11. Cherny NI, Portenoy RK (1993) Cancer pain management: current strategy. Cancer 72(Suppl 11):3393鈥?415 31201)72:11+<3393::AID-CNCR2820721606>3.0.CO;2-O" target="_blank" title="It opens in new window">CrossRef 12. Yamaguchi T, Shima Y, Morita T et al (2013) Clinical guideline for pharmacological management of cancer pain: the Japanese society of palliative medicine recommendations. Jpn J Clin Oncol 43:896鈥?09 3/jjco/hyt099" target="_blank" title="It opens in new window">CrossRef 13. Rauck RL, Tark M, Reyes E et al (2009) Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 25:2877鈥?885 85/03007990903368310" target="_blank" title="It opens in new window">CrossRef 14. Abstral SPC (2013) ProStrakan Ltd, Galashiels, UK 15. Abstral SPC (2013) Galena Biopharma, Inc., Lake Oswego, US 16. Todd KH, Funk JP (1996) The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 3:142鈥?46 3-2712.1996.tb03402.x" target="_blank" title="It opens in new window">CrossRef
刊物类别:Medicine
刊物主题:Medicine & Public Health Oncology Surgical Oncology Radiotherapy Diagnostic Radiology Internal Medicine Pathology